COMP <GO>
IMVT vs JNJ // RSI-14 & 200D SMA MOMENTUM
Immunovant Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: IMVT 3
— JNJ 10
▲ RSI-14 & 200D SMA MOMENTUM LEADER: JNJ
LAST: $29.17 (-1.59%) • MKT CAP: $6.12B
rsi-technicals
39.6
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
rsi-technicals
60.4
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IMVT VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IMVT | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 25.50% | -60.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.65% | 2.97% | -9.62 | JNJ | /fcf-yield <GO> |
| Operating Margin | -36.00% | 34.70% | -70.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -29.50% | 28.50% | -58.00 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 9.90% | 6.00% | +3.90 | IMVT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.59 | +20.41 | IMVT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 7.20% | -0.40 | IMVT | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 39.6 | 60.4 | -20.73 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 1.08 | -0.10 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 36.0x | 23.0x | +13.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.12B | $662.49B | -$656.37B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IMVT REV | JNJ REV | IMVT GROSS % | JNJ GROSS % | IMVT FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $94.19B | — | 67.9% | -$407.3M | $19.70B |
| FY 2024 | $0 | $88.82B | — | 69.1% | -$376.6M | $19.84B |
| FY 2023 | $0 | $85.16B | — | 44.0% | -$214.2M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IMVT // BETA 0.98
JNJ // BETA 1.08